Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$41.87
+1.3%
$30.30
$16.50
$43.58
$3.60BN/A11,313 shs5,040 shs
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$50.96
+1.0%
$28.84
$10.14
$56.83
$1.02B1.14192,861 shs1.25 million shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$48.74
+2.3%
$48.11
$29.02
$58.38
$3.78B0.5870,066 shs1.42 million shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$41.44
+5.1%
$36.82
$27.23
$60.37
$3.73B0.26850,325 shs2.60 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-1.64%+6.05%+45.70%+117.63%+4,134,999,900.00%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
+4.45%+2.90%+100.04%+188.78%+328.27%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-0.69%-1.93%-8.59%+11.46%+50.17%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-0.48%+8.71%+6.05%+16.25%-4.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
4.1236 of 5 stars
3.62.00.04.63.11.70.0
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
4.291 of 5 stars
4.31.00.04.41.50.81.3
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
4.0721 of 5 stars
3.51.00.03.82.82.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
3.00
BuyN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.11
Buy$57.1412.13% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.67
Moderate Buy$65.0033.36% Upside
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2.93
Moderate Buy$87.00109.94% Upside

Current Analyst Ratings Breakdown

Latest CDTX, PTCT, RARE, and AAPG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$59.00
6/24/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/24/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$35.00 ➝ $75.00
6/24/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$50.00 ➝ $68.00
6/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$41.00 ➝ $53.00
6/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$36.00 ➝ $54.00
6/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
WBB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$45.00
6/20/2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$64.00
6/18/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$41.00
6/17/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
6/10/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
$134.35M27.15N/AN/A$0.48 per share87.23
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$1.27M808.94N/AN/A$14.92 per share3.42
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$806.78M4.79N/AN/A($14.24) per share-3.42
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$560.23M6.99N/AN/A$2.76 per share15.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
-$55.54MN/A0.00N/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$169.83M-$29.470.00N/AN/AN/A-73.04%-54.28%8/12/2025 (Estimated)
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$363.30M$6.516.57N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$569.18M-$5.880.00N/AN/A-93.04%-186.49%-36.81%7/30/2025 (Estimated)

Latest CDTX, PTCT, RARE, and AAPG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.45-$1.66+$3.79-$1.66N/AN/A
5/6/2025Q1 2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.85$10.04+$9.19N/A$437.16 million$1.18 billion
5/6/2025Q1 2025
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
N/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
3.24
1.26
1.26
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
3.87
3.87
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.89
3.85
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/A
2.40
2.24
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
60087.12 millionN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9020.16 million19.38 millionNo Data
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1,41079.26 million74.90 millionOptionable
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1,29494.54 million89.34 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ascentage Pharma Group International stock logo

Ascentage Pharma Group International NASDAQ:AAPG

$41.87 +0.52 (+1.26%)
As of 03:59 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$50.96 +0.51 (+1.01%)
Closing price 04:00 PM Eastern
Extended Trading
$49.65 -1.31 (-2.57%)
As of 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$48.74 +1.09 (+2.29%)
Closing price 04:00 PM Eastern
Extended Trading
$48.78 +0.04 (+0.09%)
As of 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Ultragenyx Pharmaceutical stock logo

Ultragenyx Pharmaceutical NASDAQ:RARE

$41.44 +2.02 (+5.12%)
Closing price 04:00 PM Eastern
Extended Trading
$30.67 -10.77 (-25.98%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.